Edgardo S. Santos, MD, FACP, FCCP

Articles

Lung Cancer Experts Detail Challenges of Cisplatin/Carboplatin Shortages

September 13th 2023

Experts discuss the challenges of the ongoing cisplatin and carboplatin shortages in the United States and detail how they are adapting in their practices.

Dr Santos on the ADAURA Trial of Adjuvant Osimertinib in EGFR-Mutant NSCLC

August 17th 2023

Edgardo S. Santos, MD, FACP, discusses key survival data from the pivotal phase 3 ADAURA trial in early-stage non–small cell lung cancer.

Dr Santos on Steps Taken to Address the Chemotherapy Shortage in the United States

August 8th 2023

Edgardo Santos MD, FACP, FCCP, discusses how cancer centers across the United States are minimizing the negative effects of the ongoing carboplatin and cisplatin shortage, and details potential next steps that should be taken to prevent drug shortages like this from occurring in the future.

Dr Santos on Testing and Treatment in NRG1 Fusion–Positive NSCLC

July 29th 2023

Edgardo Santos, MD, FACP, FCCP, discusses testing and treatment in NRG1 fusion–positive non–small cell lung cancer.

Dr Santos on Frontline Therapies in ALK+ NSCLC

July 7th 2023

Edgardo Santos, MD, FACP, FCCP, clinical affiliate associate professor, Florida Atlantic University; treasurer, Florida Society of Clinical Oncology, discusses first-line treatment options for patients with ALK-positive non–small cell lung cancer.

Dr Santos on the Evolution of Osimertinib in EGFR Mutated NSCLC

May 31st 2023

Edgardo S. Santos, MD, FACP, discusses the evolution of osimertinib in the treatment of patients with EGFR-mutated non–small cell lung cancer and the updated data that reaffirmed its role in the adjuvant setting for this patient population.

Dr Santos on the Impact of Cemiplimab With Chemotherapy in Squamous NSCLC

May 30th 2023

Edgardo S. Santos, MD, FACP, discusses the impact of treatment with cemiplimab plus chemotherapy in patients with squamous non–small cell lung cancer.

Unmet Needs and Future Directions in the Management of CIM

July 22nd 2022

Martin Dietrich, MD, PhD, and Edgardo Santos, MD, FACP, offer closing remarks on unmet needs and future directions in the management of CIM including other disease states where trilaciclib may offer myeloprotective benefit.

An Overview of Trilaciclib Safety and Patient QOL Outcomes

July 22nd 2022

Focusing the discussion on the clinical trials that led to the FDA approval of trilaciclib, experts in ES-SCLC share key insights into the drug’s safety and its effect on patient quality of life.

Trilaciclib Efficacy in the Prevention of CIM in ES-SCLC

July 15th 2022

Renowned leaders in thoracic oncology discuss efficacy data from key clinical trials that led to the FDA approval of the CDK4/6 inhibitor trilaciclib for CIM prophylaxis in ES-SCLC, including the drug’s role in later treatment lines.

Myeloprotective Benefit of CDK4/6 Inhibition in ES-SCLC

July 15th 2022

Edgardo Santos, MD, FACP, and Martin Dietrich, MD, PhD, share insights into the mechanism of action of CDK4/6 inhibitors for the prevention of myelosuppression in ES-SCLC.

Dr. Santos on the Utilization of Approved Monotherapies in NSCLC

March 17th 2022

Edgardo S. Santos, MD, FACP, discusses the utilization of approved monotherapies in non–small cell lung cancer.

Dr. Santos on Identifying Mechanisms of Resistance in Lung Cancer

October 28th 2021

Edgardo S. Santos, MD, FACP, discusses the importance of identifying mechanisms of resistance in lung cancer.

Dr. Santos on the FDA Approval of Ramucirumab/Erlotinib in EGFR-Mutant NSCLC

May 30th 2020

Edgardo S. Santos, MD, FACP, FCCP, discusses the FDA approval of the combination of ramucirumab and erlotinib for the frontline treatment of patients with metastatic non–small cell lung cancer (NSCLC) whose tumors harbor EGFR Ex19del or Ex21 substitution mutations.